Finding a cure for the diseases that cause dementia
We believe in the power of research to change the future
Our mission is to bring about the first life-changing dementia treatment by 2025. Our vision is a world where people are free from the fear, harm and heartbreak of dementia.
Diagnosis
Treatments
Causes
Risks
Symptoms
Alzheimer’s Research UK is the UK’s leading dementia research charity, dedicated to causes, diagnosis, prevention, treatment and cure. With your help we are making great progress.
Featured events
Raise money for dementia research and have a great time with one of our events.
Featured news and views
Alzheimer’s Research UK celebrates ‘Best Companies’ award
Cambridgeshire-based charity, Alzheimer’s Research UK, has been recognised as one of the Best Companies to Work for in the East of England. The charity, with its head office in Great Abington, was placed 49 on the list of 75 organisations, created by Best Companies. This comes just weeks after Alzheimer’s Research UK was named as…
Dementia charity spearheads global initiative to use wearables to revolutionise disease detection
The UK’s leading dementia research charity Alzheimer’s Research UK has today (11 February) launched a global initiative to revolutionise the early detection of neurodegenerative diseases like Alzheimer’s. The project will harness and analyse a wealth of digital data to develop signatures of disease – or “fingerprints” – that can be then detected using wearable technologies,…
New report highlights critical areas of investment for Government’s ‘Dementia Moonshot’
Alzheimer’s Research UK has launched an ambitious spending plan for the government’s ‘Dementia Moonshot’ funding pledge – with the charity outlining six priority research areas that must receive investment, if we are to find a life-changing treatment. Following the Conservatives’ election promise to double government funding for dementia research to over £160 million a year,…
Halted phase III clinical trial for Alzheimer’s shows renewed promise
Today (Tuesday 22 October) the pharmaceutical company Biogen announced they plan to file for US marketing approval of the potential Alzheimer’s drug, aducanumab. Aducanumab is an antibody designed to target amyloid, a protein that builds up in the brains of people with Alzheimer’s at an early stage in the disease process. Biogen originally halted Phase…
-
Positive lifestyle changes to help reduce the risk of developing dementia
by Theo Axford on 25th March 2020
This blog post has been cross-posted from the Garmin Blog page. We’re thrilled to announce […]
-
“It’s the highlight of my career so far – I called my mum as soon as I found out”
by Amy Lloyd on 24th March 2020
Alzheimer’s Research UK champions early career scientists. Without supporting the research […]
-
COVID-19 – The dementia research field adapts
by Dr Carol Routledge on 20th March 2020
It hardly needs to be said that the whole country is going through a very challenging time as we […]